![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAS |
Gene summary for FAS |
![]() |
Gene information | Species | Human | Gene symbol | FAS | Gene ID | 355 |
Gene name | Fas cell surface death receptor | |
Gene Alias | ALPS1A | |
Cytomap | 10q23.31 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P25445 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
355 | FAS | LZE4T | Human | Esophagus | ESCC | 9.35e-06 | 1.19e-01 | 0.0811 |
355 | FAS | LZE8T | Human | Esophagus | ESCC | 3.11e-08 | 2.93e-01 | 0.067 |
355 | FAS | LZE20T | Human | Esophagus | ESCC | 1.03e-05 | 3.08e-02 | 0.0662 |
355 | FAS | LZE22D1 | Human | Esophagus | HGIN | 6.30e-06 | 1.15e-01 | 0.0595 |
355 | FAS | LZE22T | Human | Esophagus | ESCC | 4.91e-02 | 2.67e-01 | 0.068 |
355 | FAS | LZE24T | Human | Esophagus | ESCC | 1.64e-11 | 2.72e-02 | 0.0596 |
355 | FAS | LZE6T | Human | Esophagus | ESCC | 3.85e-03 | 2.03e-01 | 0.0845 |
355 | FAS | P2T-E | Human | Esophagus | ESCC | 5.17e-36 | 8.88e-01 | 0.1177 |
355 | FAS | P4T-E | Human | Esophagus | ESCC | 7.55e-04 | 2.05e-02 | 0.1323 |
355 | FAS | P8T-E | Human | Esophagus | ESCC | 1.93e-19 | 2.75e-01 | 0.0889 |
355 | FAS | P9T-E | Human | Esophagus | ESCC | 3.13e-07 | 1.05e-01 | 0.1131 |
355 | FAS | P11T-E | Human | Esophagus | ESCC | 5.71e-06 | 3.92e-01 | 0.1426 |
355 | FAS | P15T-E | Human | Esophagus | ESCC | 2.41e-06 | 6.38e-02 | 0.1149 |
355 | FAS | P16T-E | Human | Esophagus | ESCC | 4.63e-02 | 2.46e-02 | 0.1153 |
355 | FAS | P21T-E | Human | Esophagus | ESCC | 3.15e-05 | 1.90e-01 | 0.1617 |
355 | FAS | P22T-E | Human | Esophagus | ESCC | 1.01e-03 | -2.44e-02 | 0.1236 |
355 | FAS | P23T-E | Human | Esophagus | ESCC | 4.67e-11 | 3.15e-01 | 0.108 |
355 | FAS | P24T-E | Human | Esophagus | ESCC | 4.87e-11 | 1.95e-01 | 0.1287 |
355 | FAS | P26T-E | Human | Esophagus | ESCC | 2.19e-07 | 9.14e-02 | 0.1276 |
355 | FAS | P27T-E | Human | Esophagus | ESCC | 9.86e-04 | 1.08e-01 | 0.1055 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190331111 | Liver | Cirrhotic | regulation of mRNA metabolic process | 140/4634 | 288/18723 | 1.07e-18 | 1.91e-16 | 140 |
GO:004427011 | Liver | Cirrhotic | cellular nitrogen compound catabolic process | 195/4634 | 451/18723 | 2.99e-18 | 4.94e-16 | 195 |
GO:004670011 | Liver | Cirrhotic | heterocycle catabolic process | 192/4634 | 445/18723 | 7.17e-18 | 1.12e-15 | 192 |
GO:004348412 | Liver | Cirrhotic | regulation of RNA splicing | 85/4634 | 148/18723 | 2.03e-17 | 2.83e-15 | 85 |
GO:003465511 | Liver | Cirrhotic | nucleobase-containing compound catabolic process | 171/4634 | 407/18723 | 9.07e-15 | 9.33e-13 | 171 |
GO:000640111 | Liver | Cirrhotic | RNA catabolic process | 126/4634 | 278/18723 | 4.64e-14 | 4.10e-12 | 126 |
GO:000640211 | Liver | Cirrhotic | mRNA catabolic process | 109/4634 | 232/18723 | 1.30e-13 | 1.09e-11 | 109 |
GO:004348811 | Liver | Cirrhotic | regulation of mRNA stability | 69/4634 | 158/18723 | 1.44e-07 | 3.87e-06 | 69 |
GO:004348711 | Liver | Cirrhotic | regulation of RNA stability | 73/4634 | 170/18723 | 1.44e-07 | 3.87e-06 | 73 |
GO:006101311 | Liver | Cirrhotic | regulation of mRNA catabolic process | 70/4634 | 166/18723 | 5.91e-07 | 1.30e-05 | 70 |
GO:0140053 | Liver | Cirrhotic | mitochondrial gene expression | 49/4634 | 108/18723 | 2.35e-06 | 4.31e-05 | 49 |
GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
GO:004670021 | Liver | HCC | heterocycle catabolic process | 299/7958 | 445/18723 | 2.07e-26 | 7.29e-24 | 299 |
GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
GO:001943921 | Liver | HCC | aromatic compound catabolic process | 309/7958 | 467/18723 | 1.56e-25 | 4.94e-23 | 309 |
GO:000640121 | Liver | HCC | RNA catabolic process | 201/7958 | 278/18723 | 3.88e-24 | 1.02e-21 | 201 |
GO:003465521 | Liver | HCC | nucleobase-containing compound catabolic process | 273/7958 | 407/18723 | 4.84e-24 | 1.23e-21 | 273 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0502230 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa0501030 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa0493230 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa0513039 | Esophagus | HGIN | Pathogenic Escherichia coli infection | 54/1383 | 197/8465 | 4.91e-05 | 6.15e-04 | 4.89e-04 | 54 |
hsa0516930 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa0516730 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
hsa0421020 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
hsa0517029 | Esophagus | HGIN | Human immunodeficiency virus 1 infection | 51/1383 | 212/8465 | 2.16e-03 | 1.90e-02 | 1.51e-02 | 51 |
hsa0541739 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa0516420 | Esophagus | HGIN | Influenza A | 42/1383 | 171/8465 | 3.41e-03 | 2.54e-02 | 2.02e-02 | 42 |
hsa0411510 | Esophagus | HGIN | p53 signaling pathway | 21/1383 | 74/8465 | 6.25e-03 | 4.25e-02 | 3.37e-02 | 21 |
hsa0516330 | Esophagus | HGIN | Human cytomegalovirus infection | 51/1383 | 225/8465 | 7.67e-03 | 4.63e-02 | 3.68e-02 | 51 |
hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa05022113 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa05010113 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa04932113 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa05130115 | Esophagus | HGIN | Pathogenic Escherichia coli infection | 54/1383 | 197/8465 | 4.91e-05 | 6.15e-04 | 4.89e-04 | 54 |
hsa05169114 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa05167114 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
hsa04210110 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
FASLG | FAS | FASL_FAS | FASLG | Breast | ADJ |
FASLG | FAS | FASL_FAS | FASLG | Breast | DCIS |
FASLG | FAS | FASL_FAS | FASLG | Cervix | ADJ |
FASLG | FAS | FASL_FAS | FASLG | Cervix | CC |
FASLG | FAS | FASL_FAS | FASLG | Cervix | Healthy |
FASLG | FAS | FASL_FAS | FASLG | Cervix | Precancer |
FASLG | FAS | FASL_FAS | FASLG | Endometrium | ADJ |
FASLG | FAS | FASL_FAS | FASLG | Endometrium | AEH |
FASLG | FAS | FASL_FAS | FASLG | Endometrium | EEC |
FASLG | FAS | FASL_FAS | FASLG | HNSCC | OSCC |
FASLG | FAS | FASL_FAS | FASLG | THCA | ADJ |
FASLG | FAS | FASL_FAS | FASLG | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAS | SNV | Missense_Mutation | c.682N>A | p.Asp228Asn | p.D228N | P25445 | protein_coding | deleterious(0.04) | benign(0.323) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FAS | SNV | Missense_Mutation | novel | c.783G>T | p.Glu261Asp | p.E261D | P25445 | protein_coding | tolerated(0.24) | benign(0.047) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
FAS | SNV | Missense_Mutation | c.814N>C | p.Glu272Gln | p.E272Q | P25445 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD | |
FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
FAS | SNV | Missense_Mutation | c.628N>T | p.His210Tyr | p.H210Y | P25445 | protein_coding | tolerated(1) | benign(0.119) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
FAS | SNV | Missense_Mutation | c.793G>C | p.Asp265His | p.D265H | P25445 | protein_coding | deleterious(0.02) | benign(0.136) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FAS | SNV | Missense_Mutation | rs773565107 | c.340N>A | p.Glu114Lys | p.E114K | P25445 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
FAS | SNV | Missense_Mutation | c.542T>C | p.Leu181Pro | p.L181P | P25445 | protein_coding | tolerated(0.08) | benign(0.055) | TCGA-CK-4947-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Other, specify in notes | folinic | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | MPA | PROGESTERONE | 14659903 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ALL-TRANS RETINOIC ACID | 9792441 | ||
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | VALPROIC ACID | 16328060 | ||
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CHOLECALCIFEROL | CHOLECALCIFEROL | 9811059 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | TENIPOSIDE | TENIPOSIDE | 9543255 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | VESNARINONE | VESNARINONE | 9226479 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 11437491 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | LITHIUM | LITHIUM | 15475000 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ASPIRIN | ASPIRIN | 15200494 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | BISPECIFIC ANTIBODY | 11280736 |
Page: 1 2 3 4 |